Tucson, Arizona, June 11, 2007 - Integrated Biomolecule Corporation (IBC) has acquired substantially all of the assets of PDI Analytical Laboratories, the analytical division of Large Scale Biology Corporation. Included in the purchase are two tandem mass spectrometers (LCQ and Micro Q-TOF), a MALDI-TOF and a GC/MS used to detect, identify and quantify compounds as single components and in complex mixtures. This instrumentation will augment the IBC Labs division, which has been conducting research and analytical testing of pharmaceuticals, nutritional supplements and other products for over 15 years.
In addition, Earl L. White, Ph.D., previously the Managing Director of PDI Analytical and Director of Quality Control for Large Scale Biology, has joined IBC as Vice President of Analytical and Pharmaceutical Sciences. Dr. White has authored 23 peer-reviewed papers and 37 abstracts and presentations, and has received numerous awards and recognition from such esteemed scientific organizations as the National Science Foundation and the American Chemical Society. Dr. White brings his unique experience having held senior analytical positions in both pharmaceutical development and contract analytical testing.
“Because of its accuracy and sensitivity the pharmaceutical industry has been moving from HPLC analysis to mass spectrometry,” stated Robert S. Green, IBC’s president. “This technology also enables the conducting of non-routine analyses efficiently and economically. Now, IBC makes this powerful technique available to the nutritional supplement industry.”
For additional information visit www.integratedbiomolecule.com.